3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
CNS
23
Sarcoma
9
Dermatologic
3
Thoracic
2
Lymphoid
2
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
17
Urinary Bladder Neoplasms
10
Kidney Neoplasms
6
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Muscle-invasive Bladder Cancer
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Central Nervous System Neoplasms
2
Carcinoma, Transitional Cell
2
Interventions
Bevacizumab
5
pembrolizumab
3
Paclitaxel
3
fludarabine
2
Sorafenib
2
Nivolumab
2
Gemcitabine
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
erythromycin propionate-N-acetylcysteinate
1
durvalumab
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
capmatinib
1
belzutifan
1
aflibercept
1
abiraterone
1
Thalidomide
1
Temozolomide
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Drug Therapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled